The mRNA-1283 vaccine showed a higher immune response—including in seniors—than its currently licensed vaccine, called mRNA-1273.222. Response was higher against Omicron BA.4/BA.5 as well as the original SARS-CoV-2 virus.
The FDA said in an email to CNN on Wednesday that it “has chosen to resolve this lawsuit rather than continuing to litigate over statements that are between two and nearly four years old.”
Transmission rates are still far below levels from 2022, when there were tens of thousands of cases in the US. But after a quieter year last year, experts say the US is vulnerable to increases in spread in a number of ways.
New guidelines suggest certain high-risk groups could benefit from having another dose of a COVID-19 vaccine this spring — and more frequent shots in general — while the broader population could be entering once-a-year territory, much like an annual flu shot.
Medical experts told CBC News that falling behind on the latest shots can come with health risks, particularly for individuals who are older or immunocompromised.
